Alpha Teknova Sees Q3 2026 Revenue Of $12.5M-$12.7M, Up 19% - 21% YoY

Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026.

Set forth below are certain preliminary unaudited financial results for the three months ended September 30, 2026 and as of September 30, 2026:

• Revenue for the three months ended September 30, 2026 is estimated to be within the range of $12.5 million and $12.7 million.
• Gross margin for the three months ended September 30, 2026 is estimated to be within the range of 36.0% and 38.0%.
• Adjusted EBITDA for the three months ended September 30, 2026 is estimated to be within the range of negative $1.2 million and negative $1 million.
• Cash and short term investments as of September 30, 2026 is estimated to be $16.6 million.

Teknova’s total revenue is estimated to be up 19% to 21% compared to the same period in the prior year. Teknova’s gross margin is estimated to have expanded by 500-700 basis points compared to the same period in the prior year, driven primarily by top-line growth. Teknova’s estimated Adjusted EBITDA would represent an at least 25% improvement compared to the same period in the prior year, driven by continued cost discipline.